Immunobiology of CD4+CD25+ T regulatory cells
Immunobiology of CD4+CD25+ T regulatory cells
批准号:
7224940
负责人:
Thomas R Malek
金额:
$32.32万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-05-01 至 2009-04-30
关键词:
Adoptive ImmunotherapyAdoptive TransferAdultAllogenicAntigensAutoimmune DiseasesAutoimmune ProcessAutoimmunityBiological ModelsCell CountCellsCharacteristicsDataDevelopmentElderlyEngraftmentGraft RejectionGrowthHistocompatibility Antigens Class IIHomeostasisImmuneImmunityImmunobiologyImmunosuppressive AgentsInfectious AgentInterleukin-2LaboratoriesMHC Class II GenesMusNumbersPeripheralPropertyPurposeReactionRelative (related person)Signal TransductionSpecificityT memory cellT-LymphocyteTestingTherapeuticTumor Immunitybasein vivoprevent
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The action of CD4+CD25 + T regulatory (Treg) cells represents a major mechanism to inhibit self-reactivity by suppressing autoreactive mature peripheral T cells that have escaped thymic negative selection. In spite of the ready ability to demonstrate this immunological phenomenon, comparatively little is known concerning the factors controlling Treg cell development, specificity, homeostasis, and function. Recently, our laboratory established one important principle concerning Treg cells, namely that IL-2 is essential for their development. Importantly, we showed that the adoptive transfer of CD4+CD25+Treg cells prevented the onset of the rapid and lethal autoimmune disease in IL-2Rbeta -/- mice that was accompanied by substantial expansion, followed by long-term stable engraftment, using syngeneic or fully allogeneic donor Treg cells. This result makes plain that Treg cells have considerable growth potential in vivo. Therefore, one major objective of this project is to define the mechanism responsible for the proliferation and homoeostasis of Treg cells.
The efficacy of allogeneic Tregs cells to prevent autoimmunity is of considerable practical value in developing strategies to utilize Treg cells in adoptive immunotherapy. Furthermore, as will be shown in the Preliminary Data, many Treg cells are specific for allogeneic MHC, as these cells have been selected to expand and survive in MHC-mismatched recipient mice. In principle, therefore, the TCR specificity is defined for these T reg cells, i.e. alloreactive to MHC class II. Thus, along with characterizing the immunosuppressive properties of allogeneic Tregs cells, the other major objective of this proposal is to utilize this and other model systems to investigate the specificity and diversity of the TCR as it relates to Treg cell homeostasis and suppressive activity. The specific aims are: 1) To further define the basis by which allogeneic CD4+CD25vTreg cells prevent autoimmunity in IL-2Rbeta-/- mice; 2) to characterize the growth and survival characteristics of CD4+CD25+Treg cells in vivo; and 3) to test the effect of limiting the diversity of the TCR repertoire on the development and function of Treg cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Predoctoral Training in Translational Immunology
-
批准号:10493792
-
项目类别:
-
资助金额:$10.56万
-
财政年份:2022
-
负责人:Thomas R Malek
-
依托单位:
Predoctoral Training in Translational Immunology
-
批准号:10684090
-
项目类别:
-
资助金额:$16.14万
-
财政年份:2022
-
负责人:Thomas R Malek
-
依托单位:
Bi-functional fusion proteins to regulate autoimmunity
-
批准号:10373388
-
项目类别:
-
资助金额:$23.03万
-
财政年份:2021
-
负责人:Thomas R Malek
-
依托单位:
Bi-functional fusion proteins to regulate autoimmunity
-
批准号:10528479
-
项目类别:
-
资助金额:$19.19万
-
财政年份:2021
-
负责人:Thomas R Malek
-
依托单位:
IL-2R-dependent mechanisms in regulation of Treg homeostasis and autoimmunity
-
批准号:10304194
-
项目类别:
-
资助金额:$61.94万
-
财政年份:2019
-
负责人:Thomas R Malek
-
依托单位:
Low-dose IL-2 in Established T1D
-
批准号:9761962
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:Thomas R Malek
-
依托单位:
Low dose IL-2 and human regulatory T cells
-
批准号:10061539
-
项目类别:
-
资助金额:$60.33万
-
财政年份:2017
-
负责人:Thomas R Malek
-
依托单位:
Low dose IL-2 and human regulatory T cells
-
批准号:10308487
-
项目类别:
-
资助金额:$60.33万
-
财政年份:2017
-
负责人:Thomas R Malek
-
依托单位:
Low-dose IL-2 in Established T1D
-
批准号:9544827
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:Thomas R Malek
-
依托单位:
A novel IL-2 biologic and tumor immunity
-
批准号:9185950
-
项目类别:
-
资助金额:$20.03万
-
财政年份:2015
-
负责人:Thomas R Malek
-
依托单位:
IL-2-dependent mechanisms in T1D
-
批准号:8439428
-
项目类别:
-
资助金额:$33.28万
-
财政年份:2012
-
负责人:Thomas R Malek
-
依托单位:
IL-2-dependent mechanisms in T1D
-
批准号:8554761
-
项目类别:
-
资助金额:$32.11万
-
财政年份:2012
-
负责人:Thomas R Malek
-
依托单位:
The immunobiology of CD4+ CD25+ T regulatory cells
-
批准号:8384876
-
项目类别:
-
资助金额:$35.96万
-
财政年份:2010
-
负责人:Thomas R Malek
-
依托单位:
The immunobiology of CD4+ CD25+ T regulatory cells
-
批准号:8580546
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2010
-
负责人:Thomas R Malek
-
依托单位:
The immunobiology of CD4+ CD25+ T regulatory cells
-
批准号:8039479
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2010
-
负责人:Thomas R Malek
-
依托单位:
The immunobiology of CD4+ CD25+ T regulatory cells
-
批准号:8204397
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2010
-
负责人:Thomas R Malek
-
依托单位:
The immunobiology of CD4+ CD25+ T regulatory cells
-
批准号:8769997
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2010
-
负责人:Thomas R Malek
-
依托单位:
T cell immunity and cytokine receptor signaling
-
批准号:7907205
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2009
-
负责人:Thomas R Malek
-
依托单位:
Memory T Cells in Tumpr Immunity
-
批准号:7226410
-
项目类别:
-
资助金额:$23.42万
-
财政年份:2006
-
负责人:Thomas R Malek
-
依托单位:
Immunobiology of CD4+CD25+ T regulatory cells
-
批准号:6823665
-
项目类别:
-
资助金额:$34.09万
-
财政年份:2004
-
负责人:Thomas R Malek
-
依托单位:
海外基金